CN114689761B - Method for detecting parecoxib sodium positional isomer through liquid chromatography - Google Patents
Method for detecting parecoxib sodium positional isomer through liquid chromatography Download PDFInfo
- Publication number
- CN114689761B CN114689761B CN202210602882.3A CN202210602882A CN114689761B CN 114689761 B CN114689761 B CN 114689761B CN 202210602882 A CN202210602882 A CN 202210602882A CN 114689761 B CN114689761 B CN 114689761B
- Authority
- CN
- China
- Prior art keywords
- parecoxib sodium
- solution
- isopropanol
- chromatographic column
- hexane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/30—Control of physical parameters of the fluid carrier of temperature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
- G01N2030/324—Control of physical parameters of the fluid carrier of pressure or speed speed, flow rate
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
The invention provides a method for detecting parecoxib sodium positional isomer by liquid chromatography, wherein a liquid chiral chromatographic column used in the method is a polysaccharide derivative normal phase coating type chiral chromatographic column CHIRALPAK AD-H, and a mobile phase is a mixed solution of normal hexane, isopropanol and trifluoroacetic acid. The detection method provided by the invention has the advantages that the theoretical plate number of the peak of the liquid chromatogram is excellent, the separation degree is high, and the separation degree values under different chromatographic conditions are all more than 5.
Description
Technical Field
The invention belongs to the field of pharmaceutical analysis, and relates to a method for detecting parecoxib sodium positional isomer by liquid chromatography.
Background
Parecoxib sodium, with the chemical name of N- [ [4- (5-methyl-3-phenyl-4-isoxazolyl) phenyl ] sulfonyl ] propionamide sodium salt, is a specific cyclooxygenase-2 (COX-2) inhibitor. The primary medicine is approved to be marketed in China in 2008, is the first COX-2 inhibitor capable of being administered through intravenous injection and intramuscular injection, and is mainly used for short-term treatment of postoperative pain.
The parecoxib sodium positional isomer, with the chemical name of N- [ [3- (5-methyl-3-phenyl-4-isoxazolyl) phenyl ] sulfonyl ] propionamide sodium salt, is a meta-isomer of a benzene ring generated in a sulfonation process, cannot be effectively separated from a main peak under a reverse phase chromatographic condition, has the same retention time as parecoxib sodium, but can cause the isomer to have different biological activities due to different functional group positions. Therefore, the purity of the product is strictly controlled, and the method has important clinical significance.
In the prior patent, CN104965041B discloses a high performance liquid chromatography detection method for parecoxib sodium isomer, which adopts a chromatographic column with silane bonded silica gel as a filler, and uses n-hexane-isopropanol as a flowing phase to separate and detect parecoxib sodium.
Although the parecoxib sodium positional isomer is separated and detected by the existing test method, the separation degree of the parecoxib sodium positional isomer obtained by the detection method is low, and an improvement space still exists. Therefore, how to develop a position isomer detection method which is convenient to operate and high in separation degree has important significance for quality control of parecoxib sodium.
Disclosure of Invention
The invention aims to explore various conditions of parecoxib sodium positional isomer liquid chromatography analysis, and provides a method for detecting parecoxib sodium positional isomer through liquid chromatography, so as to solve the problems of low separation degree of parecoxib sodium and positional isomer, poor separation effect and low chromatographic column efficiency in the existing method.
The invention adopts the following technical scheme:
a method for detecting parecoxib sodium positional isomer by liquid chromatography is provided, wherein the liquid phase chiral chromatographic column is a polysaccharide derivative normal phase coating type chiral chromatographic column CHIRALPAK AD-H; the mobile phase is a mixed solution of n-hexane, isopropanol and trifluoroacetic acid; the detection wavelength is 215nm to 220 nm; the flow rate of the mobile phase is 0.8 to 1.2 mL/min; the temperature of the chromatographic column is 30 to 40 ℃.
The optional chromatographic column is a liquid phase chiral chromatographic column prepared from polysaccharide derivative chiral chromatographic column CHIRALPAK AD-H,4.6mm × 250mm, and 5 μm.
The stationary phase of an alternative chromatographic column is silica gel coated with amylose-tris (3, 5-xylylcarbamate).
The temperature of the chromatographic column is preferably 30 ℃, 35 ℃ and 40 ℃; the detection wavelength is preferably 215nm, 217nm and 220 nm; the flow rate of the mobile phase is preferably 0.8mL/min, 1.0mL/min, or 1.2 mL/min.
The volume ratio of n-hexane to isopropanol is (75 to 90) to (10 to 25), and the volume ratio of trifluoroacetic acid is 0.099 of the whole mobile phase.
The mobile phase is preferably that the volume ratio of normal hexane to isopropanol is (75-85): 15-25), and the volume ratio of trifluoroacetic acid is 0.099 of the whole mobile phase.
The mobile phase is preferably (80 to 85): 15 to 20) in the volume ratio of n-hexane to isopropanol.
Preparing a test solution:
test solution preparation: precisely weighing a to-be-measured product, placing the to-be-measured product in a volumetric flask, adding absolute ethyl alcohol to dissolve and shake up, fixing the volume to a scale mark to serve as a stock solution, then placing a certain amount of the stock solution in the volumetric flask, adding a diluent n-hexane-isopropanol 90 to dilute, shaking up and fixing the volume to the scale mark.
Compared with the prior art, the detection method provided by the invention has the advantages that the theoretical plate number of the peak of the liquid chromatogram is excellent, the separation degree is high, and the separation degree values under different chromatographic conditions are all more than 5.
Drawings
FIG. 1 is a liquid chromatogram of example 1.
FIG. 2 is a liquid chromatogram of example 2.
FIG. 3 is a liquid chromatogram of example 3.
FIG. 4 is a liquid chromatogram of example 4.
FIG. 5 is a liquid chromatogram of example 5.
FIG. 6 is a liquid chromatogram of example 6.
FIG. 7 is a liquid chromatogram of example 7.
FIG. 8 is a liquid chromatogram of example 8.
FIG. 9 is a liquid chromatogram of example 9.
Detailed Description
In order to better illustrate the present invention and facilitate an understanding of the technical solutions, the present invention is described in further detail below.
The specific information of the reagent instrument used in the embodiment of the invention is as follows:
liquid chromatograph: shimadzu 10AT HPLC is equipped with UV detector;
a chromatographic column: the polysaccharide derivative normal phase coating type chiral chromatographic column CHIRALPAK AD-H,4.6mm x 250mm,5 μm.
Examples 1-9 were prepared as follows:
control solution: and (3) precisely weighing 12.5mg of parecoxib sodium positional isomer reference substance, placing the parecoxib sodium positional isomer reference substance into a 25ml measuring flask, adding absolute ethyl alcohol to dissolve and dilute the parecoxib sodium positional isomer reference substance to a scale, and shaking up to prepare a parecoxib sodium positional isomer reference substance concentrated solution. Precisely measuring 0.5ml of parecoxib sodium positional isomer reference substance concentrated solution, putting the parecoxib sodium positional isomer reference substance concentrated solution into a 50ml measuring flask, adding a solvent n-hexane-isopropanol 90 to dilute to a scale, and shaking up to obtain the parecoxib sodium positional isomer reference substance solution.
Test solution: taking about 25mg of parecoxib sodium, precisely weighing, placing in a 25ml measuring flask, adding absolute ethyl alcohol to dissolve and dilute to a scale, shaking up, and preparing into concentrated solution of parecoxib sodium test sample. 1ml of parecoxib sodium test sample concentrated solution is precisely measured, placed in a 20ml measuring flask, diluted to scale by adding a solvent n-hexane-isopropanol (90.
The measurement method is as follows:
precisely measuring 100 mu l of system applicability test solution, injecting the solution into a liquid chromatograph, recording a chromatogram, wherein the appearance sequence is a parecoxib sodium peak and a parecoxib sodium position isomer peak in sequence, the separation degree is more than 1.5, and the theoretical plate number is not less than 2000 calculated according to the parecoxib sodium peak.
In the following examples, the volumes in the mobile phase are all calculated in mL.
Example 1
The test conditions are as follows: the model of the chromatographic column is AD-H,150 multiplied by 4.6mm,5 mu m, the mobile phase is a mixed solvent of n-hexane, isopropanol and trifluoroacetic acid with the volume ratio of 80:20, the detection wavelength is 215nm, the temperature of the chromatographic column is 35 ℃, the flow rate of the mobile phase is 1 mL/min, and 100 mu L of parecoxib sodium positional isomer reference solution, test solution and system applicability test solution are respectively injected into a liquid chromatograph. The specific results are shown in Table 1, and the liquid chromatogram is shown in FIG. 1.
TABLE 1
In the data of table 1, the parecoxib sodium and parecoxib sodium positional isomers show peaks in sequence, and the separation degree is 7.870.
Example 2
The test conditions are as follows: the model of the chromatographic column is AD-H,150 x 4.6mm,5 mu m, the mobile phase is a mixed solvent of n-hexane, isopropanol and trifluoroacetic acid with the volume ratio of 80:20, the detection wavelength is 215nm, the temperature of the chromatographic column is 30 ℃, the flow rate of the mobile phase is 1 mL/min, and 100 mu L of each of parecoxib sodium positional isomer reference solution, test solution and system applicability test solution is injected into a liquid chromatograph. The specific results are shown in Table 2, and the liquid chromatogram is shown in FIG. 2.
Example 3
The test conditions are as follows: the model of the chromatographic column is AD-H,150 x 4.6mm,5 mu m, the mobile phase is a mixed solvent of n-hexane, isopropanol and trifluoroacetic acid with the volume ratio of 80:20, the detection wavelength is 215nm, the temperature of the chromatographic column is 40 ℃, the flow rate of the mobile phase is 1 mL/min, and 100 mu L of each of parecoxib sodium positional isomer reference solution, test solution and system applicability test solution is injected into a liquid chromatograph. The specific results are shown in Table 2, and the liquid chromatogram is shown in FIG. 3.
Example 4
The test conditions are as follows: the model of the chromatographic column is AD-H,150 multiplied by 4.6mm,5 mu m, the mobile phase is a mixed solvent of n-hexane, isopropanol and trifluoroacetic acid with the volume ratio of 80. The specific results are shown in Table 2, and the liquid chromatogram is shown in FIG. 4.
Example 5
The test conditions are as follows: the model of the chromatographic column is AD-H,150 x 4.6mm,5 mu m, the mobile phase is a mixed solvent of n-hexane, isopropanol and trifluoroacetic acid with the volume ratio of 80.1. The specific results are shown in Table 2, and the liquid chromatogram is shown in FIG. 5.
Example 6
The test conditions are as follows: the model of the chromatographic column is AD-H,150 x 4.6mm,5 mu m, the mobile phase is a mixed solvent of n-hexane, isopropanol and trifluoroacetic acid with a volume ratio of 80:20, the detection wavelength is 215nm, the temperature of the chromatographic column is 35 ℃, the flow rate of the mobile phase is 0.8mL/min, and 100 mu L of each of parecoxib sodium positional isomer reference solution, test solution and system applicability test solution is injected into a liquid chromatograph. The results are shown in Table 2 and the liquid chromatogram is shown in FIG. 6.
Example 7
The test conditions are as follows: the model of the chromatographic column is AD-H,150 multiplied by 4.6mm,5 mu m, the mobile phase is a mixed solvent of n-hexane, isopropanol and trifluoroacetic acid with the volume ratio of 80:20, the detection wavelength is 215nm, the temperature of the chromatographic column is 35 ℃, the flow rate of the mobile phase is 1.2 mL/min, and 100 mu L of each of parecoxib sodium positional isomer reference solution, test solution and system applicability test solution is injected into a liquid chromatograph. The results are shown in Table 2 and the liquid chromatogram is shown in FIG. 7.
Example 8
The test conditions are as follows: the model of the chromatographic column is AD-H,150 multiplied by 4.6mm,5 mu m, the mobile phase is a mixed solvent of n-hexane, isopropanol and trifluoroacetic acid with the volume ratio of 85.1. The specific results are shown in Table 2, and the liquid chromatogram is shown in FIG. 8.
Example 9
The test conditions are as follows: the model of the chromatographic column is AD-H,150 x 4.6mm,5 mu m, the mobile phase is a mixed solvent of n-hexane, isopropanol and trifluoroacetic acid with a volume ratio of 75.1. The specific results are shown in Table 2, and the liquid chromatogram is shown in FIG. 9.
Table 2 (examples 2 to 9)
As can be seen from the data in the table 2, the scheme provided by the application has the advantages of good detection effect and excellent stability, and meets the actual requirements.
Example 10
Taking 12.5mg of parecoxib sodium positional isomer reference substance, precisely weighing, placing in a 25ml measuring flask, adding absolute ethyl alcohol to dissolve and dilute to a scale, and shaking up; precisely measuring 0.5ml of the solution, placing the solution into a 50ml measuring flask, adding a solvent n-hexane-isopropanol (90); precisely measuring 0.5ml of the parecoxib sodium positional isomer reference substance stock solution, putting the parecoxib sodium positional isomer reference substance stock solution into a 50ml measuring flask, adding a solvent n-hexane-isopropanol (90.
And precisely weighing about 12.5mg of parecoxib sodium, placing the parecoxib sodium into a 25ml measuring flask, adding absolute ethyl alcohol to dissolve and dilute the parecoxib sodium to a scale, and shaking up to prepare a parecoxib sodium reference solution.
The preparation method of the sample solution with 50 percent impurity limit sample addition comprises the following steps: the method comprises the steps of precisely measuring 5ml of parecoxib sodium reference solution and 0.25ml of parecoxib sodium positional isomer reference solution, placing the parecoxib sodium reference solution and the parecoxib sodium positional isomer reference solution into a 50ml measuring flask, adding a solvent n-hexane-isopropanol (90).
The preparation method of the sample solution with 100 percent impurity limit sample addition comprises the following steps: the method comprises the following steps of precisely measuring 5ml of parecoxib sodium reference solution and 0.5ml of parecoxib sodium positional isomer reference solution, placing the parecoxib sodium reference solution and the parecoxib sodium positional isomer reference solution into a 50ml measuring flask, adding a solvent n-hexane-isopropanol (90).
The preparation method of the sample solution with 120% impurity limit sample addition comprises the following steps: accurately measuring 5ml of parecoxib sodium reference substance solution and 0.6ml of parecoxib sodium positional isomer reference substance solution, placing the parecoxib sodium positional isomer reference substance solution in a 50ml measuring flask, adding a solvent n-hexane-isopropanol (90) to dilute the solution to a scale, shaking the solution uniformly, and adding the sample solution as a 120% impurity limit.
Each concentration was made up in 3 portions in parallel.
The parecoxib sodium positional isomer reference solution, the test solution and the sample-adding test solution are measured accurately, each 100 mu L, and injected into a chromatograph to calculate the recovery rate, and the results are shown in the following table.
TABLE 3 accuracy test results
And (4) conclusion: the average recovery rate of the parecoxib sodium positional isomer is 99.6% within the limit range of 50% -120%, the RSD is 3.32%, the requirements that the recovery rate is 90% -108% and the RSD is less than 5% are met, and the accuracy of the method is good.
COMPARATIVE EXAMPLE 1 (CN 104965041B example 1)
A high performance liquid chromatography separation detection method of parecoxib sodium isomer is disclosed, wherein the volume ratio of mobile phase n-hexane-isopropanol is 70. The column was Agela Technologessissilia 4.6X 250mm,5 μm. The flow rate of the mobile phase is 1.0ml/min, the temperature of the chromatographic column is 35 ℃, and the detection wavelength is 215nm. Preparing a test solution: taking a proper amount of a test sample, precisely weighing, and preparing a solution containing 0.4mg of parecoxib sodium in each 1ml of the test sample by using a diluent as a test sample solution; preparing a reference substance solution: taking a proper amount of parecoxib sodium isomer reference substance and parecoxib sodium reference substance, precisely weighing and preparing a mixed solution containing 0.8 mu g of parecoxib sodium isomer and 0.4mg of parecoxib sodium per 1ml of diluent as a reference substance solution; and (3) detection: precisely measuring 10 mu l of reference solution, injecting the reference solution into a chromatograph, precisely measuring 10 mu l of test solution, and injecting the test solution into a liquid chromatograph, wherein the diluent is n-hexane-isopropanol with a volume ratio of 50. The comparative results are shown in Table 4.
COMPARATIVE EXAMPLE 2 (CN 104965041B example 2)
A high performance liquid chromatography separation detection method of parecoxib sodium isomer is disclosed, wherein the volume ratio of mobile phase n-hexane-isopropanol is 80. The column was Agela Technologessissilia 4.6X 250mm,5 μm. The flow rate of the mobile phase is 0.8ml/min, the temperature of the chromatographic column is 30 ℃, and the detection wavelength is 215nm. Preparing a test solution: taking a proper amount of a test sample, precisely weighing, and preparing a solution containing 0.4mg of parecoxib sodium in each 1ml of the test sample solution by using a diluent, wherein the diluent is n-hexane-isopropanol in a volume ratio of 50; preparation of a reference solution: taking a proper amount of parecoxib sodium isomer reference substance and a proper amount of parecoxib sodium reference substance, precisely weighing a mixed solution which is prepared by using a diluent and contains 0.8 mu g of parecoxib sodium isomer and 0.4mg of parecoxib sodium per 1ml as a reference substance solution, wherein the diluent is n-hexane-isopropanol, the volume ratio is 50, precisely measuring 10 mu l of the reference substance solution, injecting the reference substance solution into a chromatograph, precisely measuring 10 mu l of a sample solution, and injecting the sample solution into a liquid chromatograph. The comparative results are shown in Table 4.
COMPARATIVE EXAMPLE 3 (CN 104965041B example 3)
A high performance liquid chromatography separation detection method of parecoxib sodium isomer is disclosed, wherein the volume ratio of mobile phase n-hexane-isopropanol is 90. The column was Agela Technologessissilia 4.6X 250mm,5 μm. The flow rate of the mobile phase is 0.7ml/min, the temperature of the chromatographic column is 40 ℃, and the detection wavelength is 215nm. Preparing a test solution: taking a proper amount of a test sample, precisely weighing, and preparing a solution containing 0.4mg of parecoxib sodium per 1ml by using a diluent as a test sample solution; preparation of a reference solution: taking a proper amount of parecoxib sodium isomer reference substance and parecoxib sodium reference substance, precisely weighing and preparing a mixed solution containing 0.8 mu g of parecoxib sodium isomer and 0.4mg of parecoxib sodium per 1ml of diluent as a reference substance solution; precisely measuring 10 mul of reference solution, injecting into a chromatograph, precisely measuring 10 mul of test solution, and injecting into a liquid chromatograph, wherein the diluent is n-hexane-isopropanol with a volume ratio of 50. The comparative results are shown in Table 4.
COMPARATIVE EXAMPLE 4 (CN 104965041B example 4)
A high performance liquid chromatography separation detection method of parecoxib sodium isomer is disclosed, wherein the volume ratio of n-hexane-isopropanol of a mobile phase is 95. The column was Agela Technologessissilia 4.6X 250mm,5 μm. The flow rate of the mobile phase is 0.6ml/min, the temperature of the chromatographic column is 30 ℃, and the detection wavelength is 215nm. Preparing a test solution: taking a proper amount of a test sample, precisely weighing, and preparing a solution containing 0.4mg of parecoxib sodium in each 1ml of the test sample by using a diluent as a test sample solution; preparation of a reference solution: taking a proper amount of parecoxib sodium isomer reference substance and parecoxib sodium reference substance, precisely weighing and preparing a mixed solution containing 0.8 mu g of parecoxib sodium isomer and 0.4mg of parecoxib sodium per 1ml of diluent as a reference substance solution; precisely measuring 10 mul of reference solution, injecting into a chromatograph, precisely measuring 10 mul of test solution, and injecting into a liquid chromatograph, wherein the diluent is n-hexane-isopropanol with a volume ratio of 50. The comparative results are shown in Table 4.
TABLE 4
Taking example 1 as a comparison representation of the invention, the comparison shows that the detection method of the invention is superior to the existing detection method in both the theoretical plate number value of the main peak and the isomer peak and the separation degree value. Therefore, the method is more suitable for detecting the parecoxib sodium positional isomer.
The present invention is illustrated by the above examples and comparative examples to illustrate the operation and advantages of the method for detecting parecoxib sodium regioisomer by liquid chromatography, but the present invention is not limited to the above examples. It should be understood by those skilled in the art that any modifications, equivalent substitutions, improvements, etc. made herein are intended to fall within the scope and disclosure of the present invention.
Claims (1)
1. A method for detecting parecoxib sodium positional isomer by liquid chromatography is characterized by comprising the following steps:
A. liquid chromatography conditions:
a. using a polysaccharide derivative normal phase coating type chiral chromatographic column CHIRALPAK AD-H,4.6mm multiplied by 250mm,5 mu m;
b. the temperature of the chromatographic column is 35 ℃;
c. the mobile phase is a mixed solvent of n-hexane, isopropanol and trifluoroacetic acid with a volume ratio of 80;
d. the flow rate of the mobile phase is 0.8mL/min;
e. the detection wavelength is 215nm;
f. the sample injection volume is 100 mu L;
B. the solution preparation process comprises the following steps:
precisely weighing a to-be-measured product, placing the to-be-measured product in a volumetric flask, adding absolute ethyl alcohol to dissolve and shake the product uniformly, fixing the volume to a scale mark to obtain a stock solution, then placing a certain amount of the stock solution in the volumetric flask, adding a diluent n-hexane-isopropanol 90 to dilute the stock solution, shaking the product uniformly, and fixing the volume to the scale mark;
C. the detected parecoxib sodium positional isomer is an isomer of parecoxib sodium, and specifically is N- [ [3- (5-methyl-3-phenyl-4-isoxazolyl) phenyl ] sulfonyl ] propionamide sodium salt.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210602882.3A CN114689761B (en) | 2022-05-31 | 2022-05-31 | Method for detecting parecoxib sodium positional isomer through liquid chromatography |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210602882.3A CN114689761B (en) | 2022-05-31 | 2022-05-31 | Method for detecting parecoxib sodium positional isomer through liquid chromatography |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114689761A CN114689761A (en) | 2022-07-01 |
| CN114689761B true CN114689761B (en) | 2023-03-03 |
Family
ID=82131408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210602882.3A Active CN114689761B (en) | 2022-05-31 | 2022-05-31 | Method for detecting parecoxib sodium positional isomer through liquid chromatography |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114689761B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103604894A (en) * | 2013-11-07 | 2014-02-26 | 深圳万乐药业有限公司 | Method for separating and determining bortezomib chiral isomers through high-performance liquid chromatography |
| CN104965041A (en) * | 2015-06-11 | 2015-10-07 | 成都克莱蒙医药科技有限公司 | High performance liquid chromatography detection method for parecoxib sodium isomer |
| CN105301135A (en) * | 2015-11-20 | 2016-02-03 | 扬子江药业集团有限公司 | Method for detecting chiral isomer content of ticagrelor by high performance liquid chromatography |
| CN107966511A (en) * | 2017-11-23 | 2018-04-27 | 中山奕安泰医药科技有限公司 | The method for detecting (R) -1- (1- naphthyls) ethamine chiral isomer |
| CN113075307A (en) * | 2021-03-08 | 2021-07-06 | 瑞阳制药股份有限公司 | Detection method of propane fumarate tenofovir isomer |
| CN114062518A (en) * | 2020-07-29 | 2022-02-18 | 武汉武药制药有限公司 | Method for separating and measuring tartaric acid optical isomer content |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106362714B (en) * | 2016-10-14 | 2019-03-22 | 宁夏大学 | Silver-colored functionalization silicon substrate chiral chromatogram stationary phase and preparation method thereof |
| CN111060625B (en) * | 2019-12-31 | 2022-04-05 | 北京鑫开元医药科技有限公司 | Detection method of 2- (thiophene-2-yl) ethyl p-toluenesulfonate and isomer thereof |
| CN113866282A (en) * | 2020-06-30 | 2021-12-31 | 天津药业研究院股份有限公司 | Separation and detection method for isomer impurities in 3-halogenated-7- (4-bromobenzoyl) -1-hydro-indole and application thereof |
| CN114471496A (en) * | 2021-12-23 | 2022-05-13 | 济宁医学院 | Preparation method and application of multi-mode and multifunctional molecular cage high performance liquid chromatography stationary phase |
-
2022
- 2022-05-31 CN CN202210602882.3A patent/CN114689761B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103604894A (en) * | 2013-11-07 | 2014-02-26 | 深圳万乐药业有限公司 | Method for separating and determining bortezomib chiral isomers through high-performance liquid chromatography |
| CN104965041A (en) * | 2015-06-11 | 2015-10-07 | 成都克莱蒙医药科技有限公司 | High performance liquid chromatography detection method for parecoxib sodium isomer |
| CN105301135A (en) * | 2015-11-20 | 2016-02-03 | 扬子江药业集团有限公司 | Method for detecting chiral isomer content of ticagrelor by high performance liquid chromatography |
| CN107966511A (en) * | 2017-11-23 | 2018-04-27 | 中山奕安泰医药科技有限公司 | The method for detecting (R) -1- (1- naphthyls) ethamine chiral isomer |
| CN114062518A (en) * | 2020-07-29 | 2022-02-18 | 武汉武药制药有限公司 | Method for separating and measuring tartaric acid optical isomer content |
| CN113075307A (en) * | 2021-03-08 | 2021-07-06 | 瑞阳制药股份有限公司 | Detection method of propane fumarate tenofovir isomer |
Non-Patent Citations (3)
| Title |
|---|
| 基于高效液相色谱法的帕瑞昔布钠位置异构体测定;聂忠莉等;《成都大学学报(自然科学版)》;20160630(第02期);摘要，引言，第1-4节，图1-5 * |
| 手性固定相HPLC法测定替格瑞洛片中替格瑞洛异构体含量;倪静文等;《中国新药杂志》;20180315(第05期);全文 * |
| 替格瑞洛中异构体杂质的控制;霍立茹等;《药物分析杂志》;20171130(第11期);摘要，引言，第1-3节，图1，表2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114689761A (en) | 2022-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111983074B (en) | Method for determining peramivir intermediate isomer by using high performance liquid chromatography | |
| CN104965041A (en) | High performance liquid chromatography detection method for parecoxib sodium isomer | |
| CN114544809B (en) | HPLC (high performance liquid chromatography) detection method for chiral purity of arformoterol intermediate and enantiomer thereof | |
| CN110849980A (en) | Method for detecting content of enantiomer in isopropyl L-alanine | |
| CN114689761B (en) | Method for detecting parecoxib sodium positional isomer through liquid chromatography | |
| CN112213424A (en) | Method for simultaneously determining coexisting impurities in atorvastatin calcium intermediate | |
| CN103308636B (en) | Quality control method of D-(+)-alpha-(2-thiofuran ethylamino)-alpha-(2-chlorphenyl) methyl acetate or salt thereof and application of D-(+)-alpha-(2-thiofuran ethylamino)-alpha-(2-chlorphenyl) methyl acetate or salt thereof in clopidogrel production | |
| CN110221009B (en) | Method for measuring butylphthalide related substances by HPLC | |
| CN114324642B (en) | Method for determining dextromethorphan hydrobromide related substances | |
| CN114113412B (en) | Analysis method of posaconazole impurity related substances | |
| CN114544810A (en) | HPLC detection method for chiral purity of paluvird starting material and enantiomer thereof | |
| CN113358773B (en) | Reversed phase liquid chromatography method for detecting atomoxetine hydrochloride enantiomer | |
| CN101881755B (en) | Method for detecting esmolol hydrochlorid optical isomer by high efficiency liquid chromatography | |
| CN112763623B (en) | Method for detecting peramivir trihydrate by reversed-phase high-performance liquid chromatography | |
| CN111351886B (en) | Method for determining impurity and main medicine content in phenol sulfoethylamine medicine | |
| CN112557520B (en) | Method for detecting TGR-1-corresponding isomer in TGR-1 | |
| CN109613164B (en) | Detection method of pimavanserin tartrate | |
| CN110031583B (en) | Liquid chromatography method for separating and measuring N-succinyl tryptophan enantiomer | |
| CN113419006B (en) | Liquid phase analysis method of aprepitant optical isomer | |
| CN105823828A (en) | Detection method of 1-(carbamoyl)methyl-4-hydroxy-2-pyrrolidone chiral isomer | |
| CN104730160B (en) | A kind of Acetyl Tyrosine and the high-efficiency liquid chromatography method for detecting of optical isomer thereof | |
| CN103336072A (en) | Method for determining content of chiral active component in florfenicol | |
| CN114295768B (en) | Determination method for 10 impurities in atorvastatin mother nucleus M4 | |
| CN117783399A (en) | Detection method of avibactam intermediate 6 | |
| CN106568863A (en) | Method for separating and determining escitalopram oxalate intermediate and optical isomer thereof by using high-performance liquid chromatography |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |